Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: Results from the cancer pain outcome research study group

Clinical Journal of Pain

Volumn 27, Issue 1, 2011, Pages 9-18

  Greco, Maria Teresa ^a   Corli, Oscar ^a   Montanari, Mauro ^a   Deandrea, Silvia ^a,b   Zagonel, Vittorina ^c   Apolone, Giovanni ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

breakthrough cancer pain; epidemiology; pattern of care

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAKTHROUGH CANCER PAIN; CANCER CENTER; CANCER PAIN; CANCER PALLIATIVE THERAPY; DYING; FEMALE; HOSPICE CARE; HUMAN; ITALY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN CLINIC; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; STATISTICAL ANALYSIS; TREATMENT FAILURE;

EID: 78650908300     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e3181edc250     Document Type: Article

References (23)

1. Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care. 2009;3:1-6.
2. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273-281.
3. Mercadante S, Radbruch I, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European association for Palliative Care. Cancer. 2002;94:832-839.
4. Zeppetella G, Ribeiro MDC. The pharmacotherapy of cancer-related episodic pain. Expert Opin Pharmacother. 2003;4: 493-502.
5. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP task force on cancer pain. International Association for the Study of Pain. Pain. 1999;82:263-274.
6. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129-134.
7. Zeppetella G, Ribeiro MDC. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev. 2006;25(1):CD004311.
8. Apolone G, Corli O, Caraceni A, et al. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer. 2009;100: 1566-1574.
9. Apolone G, Bertetto O, Caraceni A, et al. Pain in cancer. An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients. Health QoL Life Outcomes. 2006;14;4:88.
10. Sittl R, Likar P, Poulsen-Nautrup B. Equipotent doses of transdermal buprenorphine in patients with cancer and non-cancer pain: results from a retrospective cohort study. Clin Ther. 2005;27:225-237.
11. Clivio L, Tinazzi A, Mangano S, et al. The contribution of information technology: towards a better clinical data management. Drug Dev Res. 2006;67:245-250.
12. Cleeland CS. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, editors. Issue in Pain Measurement. New York: Raven Press; 1989:391-403.
13. Fainsinger RL, Nekolaichuk CL, Lawlor PG, et al. A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manage. 2005;29:224-237.
14. Lemeshow S, Hosmer DW, Klar J, et al. Adequacy of Sample Size in Health Studies. Chichester: John Wiley and Sons; 1990.
15. Mercadante S, Costanzo BV, Fusco F, et al. Breakthrough pain in advanced cancer patients followed at home: a longitudinal study. J Pain Symptom Manage. 2009;38:554-560.
16. Swanwick M, Haworth M, Lennard RF. The prevalence of episodic pain in cancer: a survey of hospice patients on admission. Palliat Med. 2001;15:9-18.
17. Zeppetella G, O' Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000; 20:87-92.
18. Fine PG, Busch MA. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage. 1998;16:179-183.
19. Gomez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage. 2002;24: 45-52.
20. Petzke F, Radbruch L, Zech D, et al. Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic. J Pain Symptom Manage. 1999; 17:391-401.
21. Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 2003;101:55-64.
22. Jordhoy MS, Kaasa S, Fayers P, et al. Challenge in palliative care research; recruitment, attrition and complications: experience from a randomized controlled trial. Palliat Med. 1999; 13:299-310.
23. Apolone G, Corli O, Negri E, et al. Effects of transdermal buprenorphine on Patients-reported outcomes in Cancer patients results from the Cancer Pain Outcome Research (CPOR) study group. Clin J Pain. 2009;25:671-682.